NEWS
Implications of Cannabis Legalization for the US Federal Budget
Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.
Amicus Brief in Moore v. United States
In December, the Supreme Court will hear oral arguments in Moore v. United States, a case to determine whether the mandatory repatriation tax (MRT) is constitutional.
Biosimilars – Keys to Success in the Pharmacy Benefit
Alex Brill recently joined the GRx+Biosims 2023 conference panel to discuss biosimilars and the keys to success in the pharmacy benefit.
New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
In a new white paper, Alex Brill details the consequences of regulatory uncertainty for businesses and provides a close look at the ongoing uncertainty facing companies owned by ESOPs.
MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
MGA latest white paper, by CEO Alex Brill, looks at the role of pharmacy benefit managers (PBMs) in the US prescription drug market.
Unintended Consequences of Limiting PBMs
As Congress stumbles toward a government shutdown, health policy legislation continues to simmer in the background.
‘The Price of Business’: A Major Fiscal Crisis is Brewing and Largely Ignored by the Media
Alex Brill joined Kevin Price on ‘The Price of Business’ to discuss the fact that the US will add over $1 trillion to the deficit in a single year.
1 big thing: Congress takes on PBMs
“Alex Brill, CEO of the economic consulting firm Matrix Global Advisors and a senior fellow at AEI, said it is “unnecessary” to require PBMs to pass the rebates along to plans.”
Here comes Humira competition
MGA’s analysis of the competition as new adalimumab biosimilars enter market.
Humira Competitors Don’t Guarantee Lower Patient Drug Costs
“The launches this month are “more of an inflection point in the market compared to what we saw in January when Amjevita came to market,” said Alex Brill.
The State of Biosimilars: What to Watch
Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings?
‘The Price of Business’: Discussing the Latest Inflation Report
On July 12, Alex Brill joined Kevin Price on ‘The Price of Business’ to discuss the latest inflation report. What could be behind the significant drop?
Alex Brill Interviewed on the Future of the Adalimumab Market
MGA’s Alex Brill was interviewed by Mari Serebvrov for a new piece in BioWorld to discuss the latest with the adalimumab market as new competition is expected as early as July 1.
Taking Stock of the Humira Biosimilars Market
In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.
MGA’s Alex Brill on CNBC’s Squawk Box Discussing House Republican tax proposals
Alex Brill joined CNBC’s Squawk Box to discuss Biden’s billionaire tax policy proposal and why it is not desirable for the U.S. economy.
- A Tip Exemption Is Not Sound Tax Policy
- Implications of Cannabis Legalization for the US Federal Budget
- Alex Brill Writes to FTC Regarding Interim Pharmacy Benefit Manager Report
- A Balanced Plan for Fiscal Stability and Economic Growth
- Despite Headwinds, Biosimilars Market Is Growing in 2024
- IRS says it will deny most claims of pandemic tax credit for employers
- Trump Talks Taxes and Tariffs
- Beware the Baseline Manipulator
- Patent Thicket Déjà Vu
- Will Congress Finally Act on Patent Thickets?
